

# ISO/TR 22019:2019-05 (E)

## Nanotechnologies - Considerations for performing toxicokinetic studies with nanomaterials

---

<b>Contents</b>	<b>Page</b>
Foreword.....	iv
Introduction.....	v
<b>1 Scope</b> .....	<b>1</b>
<b>2 Normative references</b> .....	<b>1</b>
<b>3 Terms and definitions</b> .....	<b>1</b>
<b>4 Abbreviations</b> .....	<b>3</b>
<b>5 Importance of toxicokinetic information for risk assessment of nanomaterials</b> .....	<b>3</b>
5.1 General.....	3
5.2 Possible use of toxicokinetic information.....	4
5.3 Key toxicokinetic issues for nanomaterials.....	5
<b>6 Factors influencing the toxicokinetics of nanomaterials</b> .....	<b>5</b>
6.1 Dissolution rate.....	5
6.2 Physical chemical properties determinant for toxicokinetic behavior.....	6
<b>7 Analytical challenges</b> .....	<b>10</b>
7.1 General.....	10
7.2 Analysis of element.....	10
7.3 Analysis of element radiolabel or fluorescence label.....	11
7.4 Determination of particles.....	12
7.5 Limit of detection.....	13
<b>8 Issues relevant for dosing conditions</b> .....	<b>13</b>
8.1 General.....	13
8.2 Dose metrics.....	14
<b>9 Absorption of nanomaterials</b> .....	<b>15</b>
9.1 General.....	15
9.2 Skin.....	15
9.3 Gastrointestinal (GI) tract.....	16
9.4 Respiratory tract.....	18
<b>10 Distribution</b> .....	<b>22</b>
10.1 General.....	22
10.2 Organ distribution.....	22
10.3 Transport across the placenta, BBB and to reproductive organs.....	23
<b>11 Metabolism/degradation</b> .....	<b>24</b>
<b>12 Excretion</b> .....	<b>24</b>
<b>13 Conclusions</b> .....	<b>25</b>
<b>Annex A (informative) Definitions as used in OECD Test Guideline 417:2010</b> .....	<b>29</b>
<b>Annex B (informative) Quantitation methods for nanomaterials, advantages and challenges</b> .....	<b>32</b>
<b>Bibliography</b> .....	<b>39</b>